You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Heart Rate Variability Analysis Using Polynomial Network
SBC: ABTECH CORPORATION Topic: N/AHigh-risk newborn infants in an intensive care unit often suffer significant morbidity and mortalitybecause of infectious illnesses which elude early diagnosis and are present in advanced stages withcirculatory shock. Earlier diagnosis and therapy might present in advanced stages with circulatoryshock. Earlier diagnosis and therapy might prevent or reduce late complications and deaths. A strategyf ...
SBIR Phase I 1994 Department of Health and Human Services -
HEART RATE VARIABILITY ANALYSIS USING POLYNOMIAL NETWORK
SBC: ABTECH CORPORATION Topic: N/AN/A
SBIR Phase I 1996 Department of Health and Human Services -
Ultra-High-Density Arrays for Genome Research
SBC: Accelerator Technology Corporation Topic: N/AWe will develop porous silicon based detector chips for the identification of biomoleculefragments. Patches of porous silicon on a silicon wafer act as active sieves, loaded with taggingmolecules, where during passage through it biomolecule fragments are identified by their response afterattachment of a tag to a modulated electric field applied across the porous patch. This technique, ifsuccessful ...
SBIR Phase I 1994 Department of Health and Human Services -
VLST FLUID SYSTEM FOR DEPOSITION OF DNA PROBE ARRAYS
SBC: Accelerator Technology Corporation Topic: N/AN/A
SBIR Phase I 1996 Department of Health and Human Services -
PORTABLE NON-INVASIVE ACOUSTIC IDENTIFICATION OF STROKE
SBC: Active Signal Technologies, Inc. Topic: N/ADESCRIPTION (provided by applicant): Active Signal Technologies, in partnership with the Brain Attack Team of the University of Maryland Medical Center, proposes to refine and test a novel portable, non-invasive system that will enable rapid identification of stroke. Approximately 750,000 people suffer a stroke each year and over 80% of these are ischemic. Yet only 1% of this number receives medi ...
SBIR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
LONG RANGE COST ESTIMATE MODEL FOR SOCIAL SECURITY
SBC: Actuarial Research Corporation Topic: N/AN/A
SBIR Phase I 1997 Department of Health and Human Services -
LONG RANGE POPULATION PROJECTION BY DISABILITY STATUS
SBC: Actuarial Research Corporation Topic: N/AN/A
SBIR Phase I 1996 Department of Health and Human Services -
PSO ACTUARIAL RATE MODEL FOR MEDICARE RISK CONTRACTS
SBC: Actuarial Research Corporation Topic: N/AN/A
SBIR Phase I 1997 Department of Health and Human Services -
NOVEL ADENOSINE A2A AGONISTS IN RENAL TISSUE PROTECTION
SBC: ADENOSINE THERAPEUTICS, LLC Topic: N/ADESCRIPTION (provided by applicant): The development of new treatments for the effective reduction of renal injury associated with acute renal failure and kidney transplantation will have a great impact on health care delivery to patients with renal disease. Acute ischemic renal failure affects 5 percent of hospitalized patients and has a mortality rate approaching 50 percent. At present, dialysis ...
SBIR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
A2A ADENOSINE AGONIST ADJUNCT FOR SYSTEMIC ANTHRAX
SBC: ADENOSINE THERAPEUTICS, LLC Topic: N/ADESCRIPTION (provided by applicant): This project develops A2A adenosine receptor (A2AAR) agonists as adjuncts to antibiotics for the treatment of anthrax septicemia. It responds to the urgent need for better treatment of highly lethal infections by this bioterrorism/biowarfare agent. Phase I has two aims, pharmaceutical development and documentation of efficacy in clinically relevant settings. Th ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
